Comprehensive assessment of P21 polymorphisms and lung cancer risk

Journal of Human Genetics

Volumn 53, Issue 1, 2008, Pages 87-95

  Choi, Yi Young ^a   Kang, Hyo Kyung ^b   Choi, Jin Eun ^a   Jang, Jin Sung ^a   Kim, Eun Jin ^b   Cha, Sung Ick ^b   Lee, Won Kee ^a   Kam, Sin ^a   Kim, Chang Ho ^b   Han, Sung Beom ^c   Jung, Tae Hoon ^b   Park, Jae Yong ^a,b  

^a Kyungpook National University School of Medicine   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c Keimyung University   (South Korea)

Author keywords

Genetic susceptibility; Lung cancer; P21; Polymorphism

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; P21 GENE; RISK ASSESSMENT;

AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 38549128862     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-007-0222-6     Document Type: Article

References (32)

1. Caputi M, Esposito V, Baldi A, De Luca A, Dean C, Signoriello G, Baldi F, Giordano A (1998) P21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. Am J Respir Cell Mol Biol 18:213-217
2. den Dunnen JT, Antonarakis E (2001) Nomenclature for the description of human sequence variations. Hum Genet 109:121-124
3. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
4. el-Deiry WS, Harper JW, O'Conner PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y et al (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174
5. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype blocks in the human genome. Science 296:2225-2229
6. Graña X, Reddy EP (1995) Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11:211-219
7. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266:1821-1828
8. Hiyama H, Iavarone A, Reeves SA (1998) Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F. Oncogene 16:1513-1523
9. Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen YJ, Yu CC, Wu TT, Lee YH, Huang JK, Hunag CH (2004) p53 codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 13:2217-2224
10. Kibel AS, Suarez BK, Belani J, Oh J, Webster R, Brophy-Ebbers M, Guo C, Catalona WJ, Picus J, Goodfellow PJ (2003) CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res 63:2033-2036
11. Kong EK, Chong WP, Wong WHS, Lau CS, Chan TM, Ng PKM, Song YQ, Mak W, Lau YL (2007) p21 gene polymorphisms in systemic lupus erythematosus. Rheumatol 46:220-226
12. Lai KC, Chen WC, Jeng LB, Li SY, Chou MC, Tsai FJ (2005) Association of genetic polymorphisms of MK, IL-4, p16, p21, p53 genes and human gastric cancer in Taiwan. Eur J Cancer Surg 31:1135-1140
13. Lee CT, Kang KH, Koh Y, Chang J, Chung HS, Park SK, Yoo KY, Song JS (2000) Characteristics of lung cancer in Korea, 1997. Lung Cancer 30:15-22
14. Li R, Waga S, Hannon GJ, Beach D, Stillman B (1994) Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534-537
15. Li G, Liu Z, Sturgis EM, Shi Q, Chamberlain RM, Spitz MR, Wei Q (2005) Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 26:1596-1602
16. Na II, Rho JK, Choi YJ, Kim CH, Park JH, Koh JS, Ryoo BY, Yang SH, Lee JC (2007) The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression. Lung Cancer 57:96-102
17. Park JY, Park JM, Jang JS, Choi JE, Kim KM, Cha SI, Kim CH, Kang YM, Lee WK, Kam S, Park RW, Kim IS, Lee JT, Jung TH (2006a) Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet 15:1963-1971
18. Park SH, Choi JE, Kim EJ, Jang JS, Lee WK, Cha SI, Kim CH, Kam S, Kim DS, Park RW, Kim YC, Han SB, Jung TH, Park JY (2006b) Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 54:303-308
19. Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B (1996) Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 10:1945-1952
20. Popanda O, Edler L, Waas P, Schattenberg T, Butkiewicz D, Muley T, Dienemann H, Risch A, Bartsch H, Schmezer P (2007) Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer 55:25-34
21. Pruneri G, Pignataro L, Carboni N, Buffa R, Di Finizio D, Cesana BM, Neri A (1999) Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. J Clin Oncol 17:3150-3159
22. Roh JW, Kim MH, Kim JW, Park NH, Song YS, Kang SB, Lee HP (2001) Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer Lett 165:59-62
23. Roh JW, Kim JW, Park NH, Song YS, Park IA, Park SY, Kang SB, Lee HP (2004) p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol 93:499-505
24. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G-phase progression. Genes Dev 13:1501-1512
25. Shih CM, Lin PT, Wang HC, Huang WC, Wang YC (2000) Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res 91:9-15
26. Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, Miyahara R, Nakagawa T, Kawano Y, Ishikawa S, Katakura H, Wada H (2002) Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 18:3865-3871
27. Sjalander A, Birgander R, Rannug A, Alexandrie AK, Tornling G, Beckman G (1996) Association between the p21 codon 31 A1 (arg) allele and lung cancer. Hum Hered 46:221-225
28. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989
29. Su L, Liu G, Zhou W, Xu LL, Miller DP, Park S, Lynch TJ, Wain JC, Christiani DC (2003) No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 12:174-175
30. Waga S, Hannon GJ, Beach D, Stillman B (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578
31. Wu MT, Wu DC, Hsu HK, Kao EL, Yang CH, Lee JM (2003) Association between p21 codon 31 polymorphism and esophageal cancer risk in a Taiwanese population. Cancer Lett 201:175-180
32. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993) p21 is a universal inhibitor of cyclin kinase. Nature 366:701-704